Extensively Hydrolyzed Formula for Infant Growth

Not yet recruiting at 10 trial locations
AB
Overseen ByAmy Benson
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how well babies grow and tolerate a new infant formula compared to an existing one. The study focuses on an extensively hydrolyzed casein formula (INV-eHCF), where cow milk proteins are broken down into smaller pieces to aid digestion. Researchers will monitor the baby's growth, stool patterns (including frequency and consistency), formula intake, and any reactions such as spit-up or fussiness. Babies aged 10 to 14 days, born full-term, and formula-fed may qualify. As an unphased trial, this study provides a unique opportunity to contribute to the understanding of infant nutrition and formula development.

Do I have to stop my baby's current formula for the trial?

Yes, your baby will need to exclusively use the study formula during the trial.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that formulas made from extensively broken-down milk proteins are generally safe and well-tolerated by infants. These formulas are designed for babies allergic to cow's milk. Studies have found that infants consuming these formulas, like the one tested in this trial, usually do not experience serious side effects. For instance, one study found that babies with milk allergies tolerated the formula well, grew normally, and encountered no major safety issues.

Another study demonstrated that babies on this type of formula grew normally and experienced fewer allergy symptoms, indicating the formula's safety for infant nutrition. Although the FDA has not yet approved this specific formula, past research on similar formulas supports its safety.12345

Why do researchers think this study treatment might be promising?

Researchers are excited about the extensively hydrolyzed casein formula (INV-eHCF) because it offers a potential new approach for supporting infant growth, especially for those with specific dietary needs. Unlike standard infant formulas, this treatment uses a process that breaks down proteins into smaller pieces, which can make it easier for infants with allergies or sensitivities to digest. This unique formulation may provide essential nutrients while minimizing the risk of allergic reactions, setting it apart from commercially available extensively hydrolyzed formulas.

What evidence suggests that this trial's formulas could be effective for infant growth?

This trial will compare two extensively hydrolyzed casein formulas for infants. Studies have shown that formulas made from broken-down milk proteins, known as extensively hydrolyzed casein formulas, benefit babies with cow's milk allergies. Research indicates that these formulas support growth as effectively as regular formulas, with similar weight and height gains. Specifically, one study found that 77% of babies using these special formulas managed their allergies well over two years. Additionally, babies on these formulas typically experience fewer allergy symptoms compared to those on regular cow's milk formulas. Overall, these formulas aim to support growth while reducing allergy risks.16789

Who Is on the Research Team?

VF

Veronica Fabrizio, DO

Principal Investigator

Mead Johnson Nutrition

Are You a Good Fit for This Trial?

This trial is for healthy, full-term infants (born between 37 and 41 weeks) who are single births, weigh between 2500g and 4200g at birth, are exclusively formula-fed by about two weeks old, and have no major health issues or feeding problems. Parents must agree to use only the study formula and be able to participate in remote visits.

Inclusion Criteria

Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive
Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age
Decentralized participant's parent/caregiver or legal guardian anticipates having a second adult available for all remote visits
See 9 more

Exclusion Criteria

History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food by mouth, the normal growth and development of the infant, or the evaluation of the infant
Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization
First degree relative (if known) history of cow's milk protein intolerance or allergy
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Infants consume either the investigational or control extensively hydrolyzed casein formula

16 weeks
Regular monitoring visits

Follow-up

Participants are monitored for growth and tolerance outcomes after treatment

up to 5 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Extensively hydrolyzed casein formula (INV-eHCF)

Trial Overview

The study compares a new extensively hydrolyzed cow milk protein infant formula (not yet FDA-approved) with a similar currently available formula. Infants will be randomly assigned to one of the formulas to see how each affects growth, digestion, tolerance, and overall health.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Extensively hydrolyzed casein formula (INV-eHCF)Experimental Treatment1 Intervention
Group II: Extensively hydrolyzed casein formula (C-eHCF), commercially availableActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mead Johnson Nutrition

Lead Sponsor

Trials
80
Recruited
15,900+

Citations

Growth, tolerance and safety outcomes with use of an ... - PMC

To evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cow's milk protein allergy ...

Real-life data on the effectiveness of extensively ...

Conclusion: EHF and AAF provided similar increases in the weight-for-age, height-for-age, and BMI-for-age z-scores in both groups. The monthly ...

Infant Formulas With Partially or Extensively Hydrolyzed Milk ...

Meta-analysis of 3 studies revealed that infants fed EHF had lower risk of cow's milk allergy than those fed CMF in children aged <2 y (RR: 0.62; 95% CI: 0.39, ...

NCT07513506 | Extensively Hydrolyzed Formula Growth ...

The purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively ...

Effectiveness of using an extensively hydrolyzed casein ...

At 24 months after starting a formula, 77% of eHCF LGG-fed infants were estimated to have been successfully managed compared with 63% of eHWF- ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37601126/

Growth, tolerance and safety outcomes with use of an ...

eHCF was well-accepted and tolerated by an intended use population of infants ≤ 6 months of age with CMPA and enabled adequate volume consumption and improved ...

Safety of a thickened extensive casein hydrolysate formula

The eCHF fulfills the criteria of a hypoallergenic formula and the NT- and T-eCHF reduced CMA symptoms. Growth was within normal range. Introduction. Cow's milk ...

Safety of a new extensively hydrolysed formula in children ...

Because children with persistent and proven IgE mediated CMA did not show adverse reactions after consumption of a new extensively hydrolyzed formula (Frisolac ...

Infants Fed Extensively Hydrolyzed Casein-Based ...

This is a randomized, controlled, double-blind, multicenter parallel study to evaluate the growth, tolerance and compliance of healthy infants fed infant ...